Since abnormal choline accumulation in cancer cells has been strongly correlated with malignant tumor growth, researchers from Tokyo Medical University aimed to analyze the functional expression of choline transporters in human hepatocellular carcinoma (HCC).
Metabolic-associated fatty liver disease (MAFLD) has emerged as a leading cause of progressive liver disease, even leading to a risk of hepatocellular carcinoma (HCC). Animal models that mimic the key etiological and histological features of the liver in the context of metabolic dysfunction represent the basis of preclinical research in MAFLD. The aim of work from researchers at Guangdong Pharmaceutical University was to develop a diet-induced murine model of MAFLD progressing to fibrosis and HCC.
Glypican 3 (GPC3) is overexpressed in hepatocellular cancers (HCC), even at very early stages. In contrast, GPC3 is not expressed in normal adult organs. One strategy in place for HCC consists in co-targeting GPC3 and CD3 with bispecific antibodies to activate the latter in order to attack GPC3-positive cancer cells.
A Nanjing University of Chinese Medicine research team has discovered novel compounds being evaluated as potential anti-hepatocellular carcinoma (anti-HCC) agents.
Cofactor Genomics Inc. opened the non-small-cell lung cancer portion of its study of the Oncoprism test, which predicts response to immunotherapy. The Predicting Immunotherapy Efficacy from Analysis of Pre-treatment Tumor Biopsies (PREDAPT) trial will study the test’s predictive ability in 11 cancers in total.
Researchers from Fudan University presented data from a study that aimed to assess the significance of a newly found long noncoding RNA (lncRNA), Ewing sarcoma-associated transcript 1 (EWSAT1), in hepatocellular carcinoma (HCC) metastasis.
Researchers from Aligos Therapeutics Inc. have described the discovery of novel liver-targeted oral PD-L1 small-molecule inhibitors for the treatment of chronic hepatitis B and liver cancers.
Qingdao Ruiji Medical Technology Co. Ltd. has identified benzofuran derivatives acting as farnesoid X receptor (FXR) agonists reported to be useful for the treatment of cancer, inflammation, metabolic, cardiovascular, liver, inflammatory bowel and renal diseases.
MGFB, a subsidiary of Fairwinds Bio, has entered into a patent license agreement with Mayo Clinic to advance experimental cancer vaccine therapeutics based on a novel platform developed at Mayo.
